Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK) 
Company Research Source: Business Wire
- Latest real-world data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gut-selective biologic vedolizumab in biologic-naïve patients with moderately to severely active ulcerative colitis or Crohn’s disease  OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from a retrospective chart review study (EVOLVE), which investigated the likelihood of serious adverse events and serious infections with vedolizumab and anti-tumor necrosis factor-alpha (anti-TNFa) therapies in biologic-naïve patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD) in real-world clinical practice. These data were announced in an oral presentation at UEG Week 2019, held in Barcelona, Spain.Data from over 1,000 biologic-naïve patients with UC or CD receiving vedolizumab or an anti-TNFa therapy (adalimumab, infliximab, golimumab, or certolizumab pegol) were collected, Show less Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for TAK alerts
Opt-in for
TAK alerts

from News Quantified
Opt-in for
TAK alerts

from News Quantified